Featured Trial

Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive Disorder

Study Identifier:

405-201-00062

ClinicalTrials.gov Identifier:

EudraCT Identifier:

N/A

Sponsor:

Otsuka Pharmaceutical Development & Commercialization, Inc.

Study Contact Information:

Recruiting

Therapeutic Area

Depression

Study Drug

Drug: Centanafadine

Drug: Escitalopram

Drug: Placebo

Estimated Enrollment

336

Phase

Phase 2

Type

Interventional

Trial Dates

Sep 2022 - Jan 2025

Study Locations

Location

Status

Location

For additional information regarding sites, contact 844-687-8522

Austin, Texas, United States, 78754

Status

Recruiting